No photo of Simona Bramante

Simona Bramante

PhD

20122018

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Fields of Science

  • 3122 Cancers
  • 1184 Genetics, developmental biology, physiology
  • 3111 Biomedicine

International and National Collaboration Publications and projects within past five years.

Publications

Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability

Valimaki, N., Kuisma, H., Pasanen, A., Heikinheimo, O., Sjoberg, J., Butzow, R., Sarvilinna, N., Heinonen, H-R., Tolvanen, J., Bramante, S., Tanskanen, T., Auvinen, J., Uimari, O., Alkodsi, A., Lehtonen, R., Kaasinen, E., Palin, K. & Aaltonen, L. A., 18 Sep 2018, In : eLife. 7, 50 p., 37110.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

CD40L coding oncolytic adenovirus 3 is a potent facilitator of dendritic cell therapy.

Zafar, S., Siurala, M. O., Sorsa, S., Hemminki, O. J., Havunen, R. S. A., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A-M. & Hemminki, A. E., 2017.

Research output: Conference materialsPoster

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

Zafar, S., Parviainen, S., Siurala, M., Hemminki, O., Havunen, R., Tahtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A. & Hemminki, A., 2017, In : OncoImmunology. 6, 2, 11 p., 1265717.

Research output: Contribution to journalArticleScientificpeer-review

Preclinical studies of oncolytic adenovirus 3 coding for CD40L as an enabler of dendritic cell therapy.

Zafar, S., Siurala, M. O., Sorsa, S., Hemminki, O. J., Havunen, R. S. A., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A-M. & Hemminki, A. E., 2017.

Research output: Conference materialsPoster

Adenoviral Delivery of Tumor Necrosis Factor-alpha and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma

Siurala, M., Havunen, R., Saha, D., Lumen, D., Airaksinen, A. J., Tähtinen, S., Cervera-Carrascon, V., Bramante, S., Parviainen, S., Vaha-Koskela, M., Kanerva, A. & Hemminki, A., Aug 2016, In : Molecular therapy. 24, 8, p. 1435-1443 9 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access

Activities

  • 1 Public Talks

American Society of Gene & Cell Therapy (ASGCT) 17th annual meeting

Simona Bramante (Speaker: Presenter)
21 May 201424 May 2014

Activity: Participating in or organising an event typesPublic Talks